Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.

RATIONALE The duration of antibiotic therapy in critically ill patients with sepsis can result in antibiotic overuse, increasing the risk of developing bacterial resistance. OBJECTIVES To test the hypothesis that an algorithm based on serial measurements of procalcitonin (PCT) allows reduction in the duration of antibiotic therapy compared with empirical rules, and does not result in more adverse outcomes in patients with severe sepsis and septic shock. METHODS In patients randomly assigned to the intervention group, antibiotics were stopped when PCT levels had decreased 90% or more from the initial value (if clinicians agreed) but not before Day 3 (if baseline PCT levels were <1 microg/L) or Day 5 (if baseline PCT levels were >/=1 microg/L). In control patients, clinicians decided on the duration of antibiotic therapy based on empirical rules. MEASUREMENTS AND MAIN RESULTS Patients assigned to the PCT group had 3.5-day shorter median duration of antibiotic therapy for the first episode of infection than control subjects (intention-to-treat, n = 79, P = 0.15). In patients in whom a decision could be taken based on serial PCT measurements, PCT guidance resulted in a 4-day reduction in the duration of antibiotic therapy (per protocol, n = 68, P = 0.003) and a smaller overall antibiotic exposure (P = 0.0002). A similar mortality and recurrence of the primary infection were observed in PCT and control groups. A 2-day shorter intensive care unit stay was also observed in patients assigned to the PCT group (P = 0.03). CONCLUSIONS Our results suggest that a protocol based on serial PCT measurement allows reducing antibiotic treatment duration and exposure in patients with severe sepsis and septic shock without apparent harm.

[1]  Meta-analysis of procalcitonin for sepsis detection. , 2007, The Lancet. Infectious diseases.

[2]  M. Christ-Crain,et al.  Meta-analysis of procalcitonin for sepsis detection. , 2007, The Lancet. Infectious diseases.

[3]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[4]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Goossens,et al.  Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study , 2007, The Lancet.

[6]  S. Harbarth [The effect of antimicrobial use on emergence and selection of resistance]. , 2007, Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS.

[7]  H. Evans,et al.  Cost of Gram‐negative resistance* , 2007, Critical care medicine.

[8]  M. Christ-Crain,et al.  Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. , 2007, Chest.

[9]  D. Pittet,et al.  Does antibiotic selection impact patient outcome? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Jensen,et al.  Procalcitonin increase in early identification of critically ill patients at high risk of mortality* , 2006, Critical care medicine.

[11]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[12]  M. Meisner,et al.  Markers for sepsis diagnosis: what is useful? , 2006, Critical care clinics.

[13]  Patrick Nicolas,et al.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.

[14]  C. Weenink,et al.  Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.

[15]  J. le Gall,et al.  SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description , 2005, Intensive Care Medicine.

[16]  Jonathan Cohen,et al.  The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit , 2005, Critical care medicine.

[17]  S. Hugonnet,et al.  Long-term reduction of vascular access-associated bloodstream infection. , 2005, Annals of internal medicine.

[18]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[19]  France Gauvin,et al.  Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Rello,et al.  Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality* , 2004, Critical care medicine.

[21]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[22]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[23]  K. Becker,et al.  The future diagnostic role of procalcitonin levels: the need for improved sensitivity. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  S. Hugonnet,et al.  Intensive care unit-acquired infections: Is postdischarge surveillance useful? , 2002, Critical care medicine.

[25]  D. Pittet,et al.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. , 2001, American journal of respiratory and critical care medicine.

[26]  S. Harbarth Nosocomial transmission of antibiotic-resistant microorganisms , 2001, Current opinion in infectious diseases.

[27]  S. Harbarth,et al.  Variation in Antimicrobial Utilization for Febrile Neutropenia in Cancer Patients , 2000, Infection.

[28]  M. Assicot,et al.  High serum procalcitonin concentrations in patients with sepsis and infection , 1993, The Lancet.

[29]  C. Sprung,et al.  The ACCP-SCCM consensus conference on sepsis and organ failure. , 1992, Chest.